The clinical team of Professor Binwu Ying at the Experiment Medical Department of West China Hospital recently joined efforts with the research team of Professor Bowen Ke of the Anesthesia and Critical and Emergency Lab, West China Hospital and Professor Jia Geng of the State Key Laboratory of Biotherapy to solve tough medical problems. “ As a result, they have successfully developed two diagnosis products: the 2019-nCoV Cobas Tapscreen MPX kit ( Multi-Color Fluorescence RT-PCR Method ) and the 2019-nCoV IgG / IgM Antibody Joint Detection Kit ( Colloidal Gold Method ), both of which have entered the clinical verification stage.” ( english.cd120.com )

So far, the 2019-nCoV Cobas Tapscreen MPX kits have been utilized to test 470 clinical samples ( 14 tested positive and 456 tested negative ). Whereas, the 2019-nCoV IgG / IgM Antibody Joint Detection Kits have tested 40 samples ( 15 tested positive and 25 tested negeative ). The results indicate that both kits have met the requirements of the Bureau of Disease Prevention and Control, National Health Commission.

Multi-Color Fluorescence RT-PCR Method kit was designed using novel coronavirus ORFIab gene and N gene conserved sequence as target sites. High specific detection of viral nucleic acid can eliminate the non-specific interference of other coronavirus strains, and the detection sensitivity reaches 200 copies / ml.

The Colloidal Gold Method kit, on the other hand, can rapidly detect novel coronavirus IgM / IgG antibody in human serum, plasma or whole blood in vitro.The main advantage of the product is on-site instant diagnosis ( POCT ), which can be used in community hospitals, schools and even families for early preliminary screening. In fighting against the epidemic, West China Hospital focuses on scientific and technological research and puts into full play its research strength and clinical advantages. These two products are the important achievements of WCH.